Teddi Mellencamp buscou medicamentos para perda de peso durante luta contra câncer em estágio 4

25 de abril de 2026

Reportado por IA

Teddi Mellencamp, ex-participante do Real Housewives of Beverly Hills, revelou em seu podcast que implorou ao seu médico por medicamentos GLP-1 para perda de peso enquanto lutava contra o câncer. Ela ganhou peso devido ao uso de esteroides, mas teve o pedido negado. Brincando sobre a ironia, ela comentou sobre estar vivendo seu melhor momento mesmo sem os medicamentos.

Parem tudo: Teddi Mellencamp foi muito sincera em seu podcast 'Two Ts In A Pod'. 😲 A estrela de reality show admitiu que pediu ao seu médico por GLP-1s depois que os esteroides fizeram com que ela ganhasse peso durante sua luta contra o melanoma em estágio 4. Mas não teve jeito, o médico negou o pedido, deixando-a hilariamente frustrada: 'Vocês me dizem para viver o meu melhor momento... mas cadê os meus GLP-1s?' 👀

Study finds people who use Ozempic-like drugs for weight loss face added stigma

05 de maio de 2026 Reportado por IA Imagem gerada por IA Verificado

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Study links GLP-1 drugs to lower breast cancer risk

Women taking GLP-1 medications such as Ozempic and Wegovy showed about 30 percent lower odds of developing breast cancer in a large observational study.

Trojan horse obesity drug boosts weight loss in mice

08 de maio de 2026 Reportado por IA

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

Entretenimento

Dolly Martinez of 'My 600-Lb. Life' dies at 30

Fofoca

Brandi Glanville defends Lisa Vanderpump against Scheana Shay's memoir

Saúde

Study links Ozempic to lower depression and anxiety risks

Katie Thurston shares positive liver cancer update

Katie Thurston received good news in her stage 4 breast cancer battle. Doctors found no evidence of disease in her liver. The Bachelorette star shared the update on her Boobie Broadcast channel.

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

08 de maio de 2026 Reportado por IA Verificado

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

quarta-feira, 10 de junho de 2026, 04:55h

Teddi Mellencamp buscou medicamentos para perda de peso durante luta contra câncer em estágio 4

Artigos relacionados

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Study links GLP-1 drugs to lower breast cancer risk

Trojan horse obesity drug boosts weight loss in mice

Dolly Martinez of 'My 600-Lb. Life' dies at 30

Brandi Glanville defends Lisa Vanderpump against Scheana Shay's memoir

Study links Ozempic to lower depression and anxiety risks

Katie Thurston shares positive liver cancer update

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Novo Nordisk heads to South African court over semaglutide copies

Kelly Dodd admits secret COVID vaccine and regrets it

Bethenny Frankel claps back at Sports Illustrated runway critics

Mindy Kaling opens up on weight loss and singledom

Brandi Glanville jabs at LeAnn Rimes over housewives rumors

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

Este site usa cookies